Delft takes majority interest in Rogan

Article

Delft Instruments has increased its interest in Rogan Medical Systems from 35% to 52%. Rogan, which markets its PACS software worldwide under the name HyperPACS, will continue to trade as a separate Delft operating company. Rogan already

Delft Instruments has increased its interest in Rogan Medical Systems from 35% to 52%. Rogan, which markets its PACS software worldwide under the name HyperPACS, will continue to trade as a separate Delft operating company. Rogan already collaborates with two other Delft companies: Nucletron for radiotherapy and thorax imaging and Oldelft Benelux for equipment distribution and maintenance.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.